HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial

被引:133
作者
Calmy, Alexandra [1 ]
Gayet-Ageron, Angele [1 ]
Montecucco, Fabrizio [2 ]
Nguyen, Alain [1 ]
Mach, Francois [2 ]
Burger, Fabienne [2 ]
Ubolyam, Sasiwimol [3 ]
Carr, Andrew [4 ]
Ruxungtham, Kiat [3 ,5 ]
Hirschel, Bernard [1 ]
Ananworanich, Jintanat [3 ,6 ]
机构
[1] Univ Hosp Geneva, HIV Unit, CH-1205 Geneva, Switzerland
[2] Univ Hosp Geneva, Fdn Med Res, Div Cardiol, CH-1205 Geneva, Switzerland
[3] HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand
[4] St Vincents Hosp, Sydney, NSW 2010, Australia
[5] Chulalongkorn Univ, Dept Med, Fac Med, Bangkok 10330, Thailand
[6] SE Asia Res Collaborat Hawaii, Bangkok, Thailand
基金
瑞士国家科学基金会;
关键词
cardiovascular risk; HIV; HIV-RNA replication; inflammation; marker; ACTIVE ANTIRETROVIRAL THERAPY; CELL-ADHESION MOLECULE-1; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; CHEMOKINES; PROGRESSION; PREDICTION; EVENTS; DEATH; MEN;
D O I
10.1097/QAD.0b013e32832995fa
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: Plasma soluble inflammatory molecules are associated with the risk of ischaemic cardiovascular events. We investigated whether HIV replication modified the levels of these proteins in a combination antiretroviral therapy (cART) interruption trial. Method and results: In 145 HIV-infected Thai patients (62% women, median CD4 cell count 271 cells/mu l, median plasma HIV-RNA 4.66 log(10) copies/ml) included in the Swiss-Thai-Australia Treatment Interruption Trial (STACCATO) trial, leptin, adiponectin, C-reactive protein, soluble vascular cell adhesion molecule-1 (s-VCAM-1), P-selectin, chemokine ligand 2, chemokine ligand 3, interleukin (IL)-6, IL-10, granulocyte macrophage colony-stimulating factor and D-dimer were measured before cART was initiated, after cART had suppressed HIV replication to less than 50 copies/ml plasma (median 8 months) and again 12 weeks after randomization to continued cART (n = 48) or interrupted cART (n = 97). Multiple linear regression and logistic regression were used to investigate the association between each cardiovascular marker and plasma HIV-RNA. Initiation of cART resulted in significant declines in s-VCAM-1, P-selectin, leptin and D-dimer, whereas mediators with anti-inflammatory properties, such as adiponectin and IL-10, increased. At 12 weeks after randomization, we found positive associations between levels of s-VCAM-1 and chemokine ligand 2 with an increase in plasma HIV-RNA (r = 0.271, P = 0.001 and r = 0.24, P = 0.005, respectively), whereas levels of adiponectin decreased for each 1 log increase in plasma HIV-RNA (r = -0.24, P = 0.002). Detectable IL-10 was less likely (odds ratio = 0.64, 95% confidence interval = 0.43-0.96) for each 1 log increase in plasma HIV-RNA. Conclusion: Plasma levels of several inflammatory, anti-inflammatory and endothelial activation markers of cardiovascular disease are associated with HIV-RNA replication. (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:929 / 939
页数:11
相关论文
共 48 条
  • [1] CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1:: results of the Staccato randomised trial
    Ananworanich, Jintanat
    Gayet-Ageron, Angele
    Le Braz, Michelle
    Prasithsirikul, Wisit
    Chetchotisakd, Ploenchan
    Kiertiburanakul, Sasisopin
    Munsakul, Warangkana
    Raksakulkarn, Phitsanu
    Tansuphasawasdikul, Somboon
    Sirivichayakul, Sunee
    Cavassini, Matthias
    Karrer, Urs
    Genne, Daniel
    Nueesch, Reto
    Vernazza, Pietro
    Bernasconi, Enos
    Leduc, Dominic
    Satchell, Claudette
    Yerly, Sabine
    Perrin, Luc
    Hill, Andrew
    Perneger, Thomas
    Phanuphak, Praphan
    Furrer, Hansjakob
    Cooper, David
    Ruxrungtham, Kiat
    Hirschel, Bernard
    [J]. LANCET, 2006, 368 (9534) : 459 - 465
  • [2] AN UPDATED CORONARY RISK PROFILE - A STATEMENT FOR HEALTH-PROFESSIONALS
    ANDERSON, KM
    WILSON, PWF
    ODELL, PM
    KANNEL, WB
    [J]. CIRCULATION, 1991, 83 (01) : 356 - 362
  • [3] Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease
    Ardigo, Diego
    Assimes, Themistocles L.
    Fortmann, Stephen P.
    Go, Alan S.
    Hlatky, Mark
    Hytopoulos, Evangelos
    Iribarren, Carlos
    Tsao, Philip S.
    Tabibiazar, Raymond
    Quertermous, Thomas
    [J]. PHYSIOLOGICAL GENOMICS, 2007, 31 (03) : 402 - 409
  • [4] Absence of favourable changes in circulating levels of interleukin-16 or β-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection
    Arjona, MMD
    Cano, RP
    Orozco, MJ
    Aspas, AM
    Guerrero, F
    del Alamo, CFG
    Girón-González, JA
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (01) : 57 - 62
  • [5] Chemokines and Cardiovascular Risk
    Aukrust, Pal
    Halvorsen, Bente
    Yndestad, Arne
    Ueland, Thor
    Oie, Erik
    Otterdal, Kari
    Gullestad, Lars
    Damas, Jan K.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (11) : 1909 - 1919
  • [6] Brown Pierre Antoine, 2005, J Immune Based Ther Vaccines, V3, P3, DOI 10.1186/1476-8518-3-3
  • [7] The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection
    Coll, Blai
    Parra, Sandra
    Alonso-Villaverde, Carlos
    Aragones, Gerard
    Montero, Manuel
    Camps, Jordi
    Joven, Jorge
    Masana, Lluis
    [J]. STROKE, 2007, 38 (09) : 2477 - 2484
  • [8] Function of C-reactive protein
    Du Clos, TW
    [J]. ANNALS OF MEDICINE, 2000, 32 (04) : 274 - 278
  • [9] El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360
  • [10] Soluble P-selectin as a marker of in vivo platelet activation
    Ferroni, Patrizia
    Martini, Francesca
    Riondino, Silvia
    La Farina, Francesca
    Magnapera, Agesilao
    Ciatti, Filippo
    Guadagni, Fiorella
    [J]. CLINICA CHIMICA ACTA, 2009, 399 (1-2) : 88 - 91